Clinical trials: sponsored by Celgene
Non-Small Cell Lung Cancer
A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer
Subjects who qualify will receive single agent lenalidomide once daily on days 1-21 of 28 day cycles. Subjects will continue until disease progression is documented.
- Trial name
- NCT00179686
- Testing
- CC-5013
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Celgene Corporation
Prostate Cancer
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
Phase II randomized open-label, two-arm study of safety and efficacy of CC-4047 in subjects with metastatic hormone refractory prostate cancer (HRPC)
- Trial name
- NCT00072722
- Testing
- CC-4047
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celgene Corporation
Breast Neoplasms, Metastases, Neoplasm
Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer
Paclitaxel (Taxol, Bristol-Meyers Squibb) has been shown to be very effective against metastatic breast cancer, as well as other cancers.
- Trial name
- NCT00046527
- Testing
- ABI-007
- Where
- United States
- Volunteers
- 460 people
- Sponsor
- Celgene Corporation
Ovarian Cancer
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days 1-21 when given with liposomal doxorubicin on day 1 of every 28 day cycle Phase II will commence once the MTD is established, additional…
- Trial name
- NCT00179725
- Testing
- CC-5013, liposomal doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Celgene Corporation
Prostate Cancer
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
Subjects who qualify will receive single agent oral lenalidomide daily on days 1-21 every 28 day cycle. Subjects will continue on study until documented disease progression
- Trial name
- NCT00179738
- Testing
- CC5013
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Celgene Corporation
Non-Small Cell Lung Cancer
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer
Study will deteremine the MTD and evaluate the safety profile of oral lenalidomide on days 1-14 when combined with pemetrexed on day 1 of a 21 days cycle. Subjects will continue on study until documention of disease progression.
- Trial name
- NCT00179699
- Testing
- CC-5013, pemetrexed
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Celgene Corporation
Pancreatic Cancer
A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas
Phase I will determine the MDT and evaluate the safety profile of oral lenalidomide days 1-21 and weekly gemcitabine days 1, 8, \& 15 in 28 day cycles Phase II will explore the anti-tumor activity and safety of the combination in…
- Trial name
- NCT00179751
- Testing
- CC-5013, gemcitabine
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Celgene Corporation
Melanoma, Neoplasm Metastasis
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase.
- Trial name
- NCT00055562
- Testing
- CC 5013
- Where
- 31 sites in United States, Canada
- Volunteers
- 274 people
- Sponsor
- Celgene Corporation
Fatigue, Neoplasms
D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients
To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.
- Trial name
- NCT00047476
- Testing
- dexmethylphenidate(d-mph)
- Where
- 21 sites in United States
- Volunteers
- 160 people
- Sponsor
- Celgene Corporation
Myelodysplastic Syndromes
A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes
The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).
- Trial name
- NCT00050843
- Testing
- thalidomide
- Where
- 38 sites in United States
- Volunteers
- 220 people
- Sponsor
- Celgene Corporation
HIV Infections, HIV Wasting Syndrome
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
To allow patients with HIV-associated wasting to receive thalidomide treatment at 1 of 2 doses. To gain safety and efficacy data from a broader base of patients with HIV-associated wasting in order to support Celgene's pivotal…
- Trial name
- NCT00002157
- Testing
- Thalidomide
- Where
- United States
- Sponsor
- Celgene Corporation
HIV Infections, HIV Wasting Syndrome
A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome
To evaluate the safety, antiviral and anti-TNF-alpha activity, and preliminary efficacy of thalidomide in reducing weight loss in patients with HIV wasting syndrome.
- Trial name
- NCT00002127
- Testing
- Thalidomide
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Celgene Corporation